Targeting pandemic influenza: a primer on influenza antivirals and drug resistance

被引：50

作者：

Moss, Ronald B. ^{[1
]}

Davey, Richard T. ^{[2
]}

Steigbigel, Roy T. ^{[3
]}

Fang, Fang ^{[1
]}

机构：

[1] NexBio Inc, San Diego, CA USA

[2] NIAID, NIH, Bethesda, MD 20892 USA

[3] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2010年 / 65卷 / 06期

关键词：

flu; DAS181; H274Y; oseltamivir; zanamivir; peramivir; SIALIDASE FUSION PROTEIN; NEURAMINIDASE INHIBITORS; VIRUS; EMERGENCE; THERAPY; FAVIPIRAVIR; ZANAMIVIR; DAS181; HUMANS; T-705;

D O I：

10.1093/jac/dkq100

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The emergence of the 2009 H1N1 pandemic influenza A virus, as well as constant antigenic drift of seasonal influenza, underscores the remarkable versatility of this virus in adapting to the human population. While vaccines are the principal public health defence against influenza, rapid vaccine development can be a daunting task. Antiviral drugs offer the promise of inhibiting influenza regardless of its genetic variations. However, the rapid rise of resistance to several antivirals has highlighted the need for developing novel therapeutics with reduced drug resistance potential. In this review, we will summarize the effects of the currently licensed anti-influenza drugs as well as the candidates in development against the seasonal and the 2009 H1N1 pandemic influenza A virus with an emphasis on drug resistance.

引用

页码：1086 / 1093

页数：8

共 62 条

[41] Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection [J].